iberdomide + dexamethasone + bortezomib

**Iberdomide + dexamethasone + bortezomib** is an investigational combination regimen for multiple myeloma, particularly explored in relapsed/refractory and newly diagnosed patients. **Iberdomide** is an oral cereblon E3 ligase modulator (CELMoD), which induces degradation of lymphoid transcription factors (IKZF1 and IKZF3), resulting in tumoricidal and immunostimulatory effects. **Bortezomib** is a reversible proteasome inhibitor that disrupts protein degradation and induces apoptosis in myeloma cells. **Dexamethasone** is a corticosteroid with anti-inflammatory and lympholytic properties, commonly used to potentiate anti-myeloma regimens. The combination shows synergistic efficacy and has demonstrated robust response rates in clinical trials for both newly diagnosed and relapsed/refractory multiple myeloma, including in patients who are ineligible for transplant[1][2][4][5][6][8].

Other names

IberVd